Rizatriptan: Difference between revisions

Rizatriptan
	File:Rizatriptan.svg
Clinical data
Trade names	Maxalt
AHFS/Drugs.com	Monograph
MedlinePlus	a601109
Pregnancy; category	B1 (Au), C (U.S.);
Routes of; administration	Oral
ATC code	N02CC04 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	45%
Protein binding	14%
Metabolism	by monoamine oxidase
Elimination half-life	2–3 hours
Excretion	82% urine; 12% faeces
Identifiers
	IUPAC name N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine;
CAS Number	145202-66-0 ;
PubChem CID	5078;
IUPHAR/BPS	51;
DrugBank	DB00953 ;
ChemSpider	4900 ;
UNII	WR978S7QHH;
KEGG	D00675 ;
ChEBI	CHEBI:48273 ;
ChEMBL	ChEMBL905 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C15H19N5
Molar mass	269.345 g/mol
3D model (JSmol)	Interactive image;
	SMILES n1cn(nc1)Cc2cc3c(cc2)ncc3CCN(C)C;
	InChI InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3 ; Key:ULFRLSNUDGIQQP-UHFFFAOYSA-N ;
(what is this?) (verify)

← Older edit Newer edit →

VisualWikitext

Revision as of 06:47, 10 February 2014

Rizatriptan
MAXALT^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Rizatriptan
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

For patient information about Rizatriptan, click here.

Synonyms / Brand Names: MAXALT

Overview

Rizatriptan (trade name Maxalt) is a 5-HT1 agonist triptan drug developed by Merck & Co. for the treatment of migraine headaches. It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).

Maxalt obtained approval by the United States Food and Drug Administration (FDA) on June 29, 1998. It is a second-generation triptan.

Rizatriptan is available only by prescription in Australia, Finland, the United States, Canada and New Zealand. Similarly, it is classed as a POM (Prescription Only Medicine) in the United Kingdom, Italy (as Rizaliv), Israel (as Rizalt), The Netherlands, Croatia and Spain (as Maxalt).

FDA Package Insert

MAXALT (rizatriptan benzoate) tablet

Use

Rizatriptan is used to treat acute migraine attacks with or without aura. It does not prevent future migraine attacks.

Contraindications

coronary artery disease
use of monoamine oxidase inhibitors

Adverse effects

Severe:

serotonin syndrome when used with MAOIs
coronary artery vasospasm
transient myocardial ischemia Template:Nb10
myocardial infarction
ventricular tachycardia
ventricular fibrillation
hypertensive crisis

Atypical sensations:

paresthesia

Cardiovascular:

Ear, nose, and throat:

Gastrointestinal:

diarrhea

Muscular:

myalgia

Neurological:

Respiratory:

dyspnea

Skin:

sweating

Miscellaneous:

hypersensitivity

Mechanism of Action

References

@@ Line 1: / Line 1: @@
 __NOTOC__
-{{Rizatriptan}}
+{{Rizatriptan}}{{Drugbox
+| Verifiedfields = changed
+| verifiedrevid = 464382941
+| IUPAC_name = ''N'',''N''-dimethyl-2-[5-(1''H''-1,2,4-triazol-1-ylmethyl)-1''H''-indol-3-yl]ethanamine
+| image = Rizatriptan.svg
+<!--Clinical data-->
+| tradename = Maxalt
+| Drugs.com = {{drugs.com|monograph|maxalt}}
+| MedlinePlus = a601109
+| pregnancy_category = B1 <small>([[Australia|Au]])</small>, C <small>([[United States|U.S.]])</small>
+| legal_status = Rx-only
+| routes_of_administration = Oral
+<!--Pharmacokinetic data-->
+| bioavailability = 45%
+| protein_bound = 14%
+| metabolism = by [[monoamine oxidase]]
+| elimination_half-life = 2–3 hours
+| excretion = 82% [[urine]]; 12% [[faeces]]
+<!--Identifiers-->
+| CASNo_Ref = {{cascite|correct|CAS}}
+| CAS_number_Ref = {{cascite|correct|??}}
+| CAS_number = 145202-66-0
+| ATC_prefix = N02
+| ATC_suffix = CC04
+| ATC_supplemental =
+| PubChem = 5078
+| IUPHAR_ligand = 51
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
+ | DrugBank = DB00953
+| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
+| ChemSpiderID = 4900
+| UNII_Ref = {{fdacite|correct|FDA}}
+| UNII = WR978S7QHH
+| KEGG_Ref = {{keggcite|changed|kegg}}
+| KEGG = D00675
+| ChEBI_Ref = {{ebicite|correct|EBI}}
+| ChEBI = 48273
+| ChEMBL_Ref = {{ebicite|correct|EBI}}
+| ChEMBL = 905
+<!--Chemical data-->
+| C=15 | H=19 | N=5
+| molecular_weight = 269.345 g/mol
+| smiles = n1cn(nc1)Cc2cc3c(cc2)ncc3CCN(C)C
+| InChI = 1/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3
+| InChIKey = ULFRLSNUDGIQQP-UHFFFAOYAA
+| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
+| StdInChI = 1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3
+| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
+| StdInChIKey = ULFRLSNUDGIQQP-UHFFFAOYSA-N
+}}
 {{CMG}}
 '''''For patient information about Rizatriptan, click [[Rizatriptan (patient information)|here]].'''''
-{{SB}}
+{{SB}} MAXALT
 ==Overview==
+'''Rizatriptan''' (trade name '''Maxalt''') is a [[5-HT1]] agonist [[triptan]] [[medication|drug]] developed by [[Merck & Co.]] for the treatment of [[migraine]] [[headache]]s. It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).
+Maxalt obtained approval by the United States [[Food and Drug Administration]] (FDA) on June 29, 1998. It is a second-generation triptan.
+Rizatriptan is available only by [[Medical prescription|prescription]] in [[Australia]], [[Finland]], the [[United States]], [[Canada]] and [[New Zealand]]. Similarly, it is classed as a POM (Prescription Only Medicine) in the [[United Kingdom]], [[Italy]] (as '''Rizaliv'''), [[Israel]] (as '''Rizalt'''), [[Netherlands|The Netherlands]], [[Croatia]] and [[Spain]] (as ''Maxalt'').
 ==Category==
+Antimigraine Drugs, Triptans
 ==FDA Package Insert==
 ====MAXALT (rizatriptan benzoate) tablet====
@@ Line 30: / Line 92: @@
 '''| [[Rizatriptan patient counseling information|Patient Counseling Information]]'''
 '''| [[Rizatriptan labels and packages|Labels and Packages]]'''
+==Use==
+Rizatriptan is used to treat acute [[migraine]] attacks with or without [[aura (symptom)|aura]]. It does not prevent future migraine attacks.
+==Contraindications==
+* [[coronary artery disease]]
+* use of [[monoamine oxidase inhibitor]]s
+==Adverse effects==
+{{col-begin}}{{col-break}}
+Severe:
+* [[serotonin syndrome]] when used with [[MAOI]]s
+* [[coronary artery]] [[vasospasm]]
+* transient [[myocardial ischemia]] {{nb10}}
+* [[myocardial infarction]]
+* ventricular [[tachycardia]]
+* ventricular [[fibrillation]]
+* [[hypertension|hypertensive crisis]]
+Atypical sensations:
+* [[paresthesia]]
+[[Cardiovascular]]:
+* [[palpitation]]s
+* [[Syncope (medicine)|syncope]]
+* [[hypertension]]
+* [[hypotension]]
+Ear, nose, and throat:
+* [[tinnitus]]
+* [[sinusitis]]
+* [[allergic]] [[rhinitis]]
+* [[upper respiratory tract]] [[inflammation]]
+{{col-break}}
+[[Gastrointestinal]]:
+* [[diarrhea]]
+Muscular:
+* [[myalgia]]
+Neurological:
+* [[phonophobia]]
+* [[photophobia]]
+Respiratory:
+* [[dyspnea]]
+Skin:
+* [[diaphoresis|sweating]]
+Miscellaneous:
+* [[hypersensitivity]]
+{{col-end}}
 ==Mechanism of Action==